DURAGESIC-75 Drug Patent Profile

Which patents cover Duragesic-75, and when can generic versions of Duragesic-75 launch?

Duragesic-75 is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in DURAGESIC-75 is fentanyl. There are thirty-one drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the fentanyl profile page.

Summary for DURAGESIC-75

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for DURAGESIC-75

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	DURAGESIC-75	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	019813-002	Aug 7, 1990		DISCN	Yes	No

International Patents for DURAGESIC-75

See the table below for patents covering DURAGESIC-75 around the world.

Country	Patent Number	Title	Estimated Expiration
France	2567761	DISPOSITIF D'APPORT TRANSDERMIQUE POUR L'ADMINISTRATION DE FENTANYL
Hong Kong	8191	TRANSDERMAL ADMINISTRATION OF FENTANYL AND DEVICE THEREFOR
Germany	3546869	Transdermales Abgabesystem zur Verabreichung von Fentanyl
Spain	545366
Belgium	905568

Supplementary Protection Certificates for DURAGESIC-75

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1635783	122014000024	Germany		PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
1769785	C300522	Netherlands		PRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006
0975367	122011000009	Germany		PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
0901368	C300523	Netherlands		PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006
1769785	C300521	Netherlands		PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006

Analysis of DURAGESIC-75: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

DURAGESIC-75 (fentanyl transdermal system, 75 micrograms/hour) represents a high-potency opioid analgesic indicated for managing severe pain, often in cancer patients or in palliative care. This report analyzes its current market position, growth potential, competitive landscape, regulatory environment, and financial outlook.

Key insights:

• Estimated global market size for fentanyl transdermal patches (all strengths) in 2022 was approximately USD 2.2 billion, with DURAGESIC-based products accounting for significant share.
• The product is facing market challenges due to opioid regulations, pandemic-related supply chain disruptions, and increasing preference for abuse-deterrent formulations.
• Investment prospects hinge on patent exclusivity, regulatory approvals, and evolving pain management guidelines.

Market Overview and Dynamics

Global Market Size and Growth Trends

Year	Estimated Market Size for Fentanyl Transdermal Patches (USD Billion)	Compound Annual Growth Rate (CAGR)
2020	1.8	6.4%
2022	2.2
2025 [Forecast]	3.0	14.4%

Source: [1], MarketLine Reports (2023)

Market Segmentation

• By Geography:

  • North America: 55%
  • Europe: 30%
  • Asia-Pacific: 10%
  • Rest of World: 5%

• By Indication:

  • Oncology pain management: 70%
  • Chronic non-cancer pain: 25%
  • Palliative care: 5%

Drivers of Growth

• Rising prevalence of cancer and chronic pain conditions.
• Adoption of opioid patches as non-invasive pain management.
• Increasing acceptance in palliative care settings.
• Innovations in abuse-deterrent formulations and patch technology.
• Aging populations in developed markets.

Restraints and Challenges

Issue	Impact
Opioid abuse scandals	Increased regulation, decreased prescriptions
Prescription guidelines tightening	Limits on opioid use, especially high-dose patches
Patent expirations & generics	Price erosion and market saturation
Supply chain disruptions	Manufacturing delays, impacting availability

Competitive Landscape

Key Players	Market Share (2022)	Notable Strengths
Janssen Pharmaceutica	55%	Established brand, broad distribution
Teva Pharmaceuticals	20%	Generics, price competitiveness
Pfizer	10%	Innovation, pipeline
Others	15%	Niche and emerging players

Note: Duragesic remains the branded leader, but generics are gaining traction.

Regulatory Environment

Patent and Exclusivity Status

• Duragesic's primary patents expired in late 2018, prompting generic competitors to enter markets.
• Extended exclusivity was granted via secondary patents in certain jurisdictions until 2025, covering delivery system design and abuse-deterrent features.

Regulatory Trends

• Following opioid crises in North America, authorities imposed stringent controls, including prescription monitoring programs (PDMPs).
• Recent approvals for abuse-deterrent formulations (ADFs) aim to curb misuse, potentially impacting sales of traditional DURAGESIC formulations.
• FDA's REMS program mandates strict handling, limiting distribution channels.

Market Entry Barriers

• Stringent regulatory approval processes for new formulations.
• Patent challenges and litigation from generic manufacturers.
• Market inertia owing to prescriber familiarity with existing formulations.

Financial Trajectory Analysis

Historical Revenue and Sales Trends

Year	Approximate Global Sales (USD Millions)	Remarks
2018	750	Post patent expiration trend begins
2020	700	Slight decline due to increased regulation
2022	650	Competitive pressures and regulatory challenges

Future Revenue Projections

Scenario	2023	2024	2025	Assumptions
Conservative	USD 600M	USD 580M	USD 560M	Regulatory hurdles, patent cliff, slow growth
Moderate	USD 620M	USD 650M	USD 700M	Introduction of abuse-deterrent variants, market expansion
Optimistic	USD 650M	USD 700M	USD 750M	Pipeline innovations, increased opioid approvals in emerging markets

Profitability Considerations

• Margins likely to decline due to increased costs of compliance, litigation, and price competition.
• R&D investments in abuse-deterrent and alternative formulations may reduce short-term profitability.
• Potential for revenue increase if new formulations gain regulatory approval and market acceptance.

Investment Risks

Risk Factor	Impact	Mitigation
Regulatory tightening	Revenue decline	Diversify product portfolio
Patent expiry	Price erosion	Accelerate pipeline products
Litigation	Costly legal battles	Strengthen IP portfolio
Market competition	Reduced market share	Focus on niche indications

Comparison with Similar High-Dose Opioid Patches

Product	Strengths	Market Share	Key Differentiators
DURAGESIC-75	Established brand	55%	Familiarity, extensive distribution
Fentora (transmucosal)	Faster onset	N/A	Different administration route
Generic fentanyl patches	Cost advantage	20%	Lower price point

Deep Dive: Market Entry and Growth Opportunities

Emerging Markets

• India, China, and Brazil show increasing pain management needs.
• Regulatory frameworks are evolving, with some jurisdictions easing opioid access under controlled settings.
• Growing healthcare infrastructure supports distribution of high-cost medications.

Pipeline Innovations

• Abuse-deterrent formulations with novel delivery systems.
• Extended-release formulations reducing dosing frequency.
• Digital health integration for compliance and monitoring.

Impact of Policy Changes

Policy Area	Effect	Timeline
Opioid prescribing guidelines	Reduced initiation	Ongoing, from 2020 onwards
Opioid addiction treatment funding	Potential increase in alternative therapies	Next 5 years
Patent reforms	Increased generics	Post-2025

Conclusion

The DURAGESIC-75 market is at a pivotal juncture, with declining sales margins due to patent expiries, regulatory challenges, and rising competition. Growth prospects remain viable in emerging markets and through product innovation, particularly abuse-deterrent formulations. Investors must closely monitor policy shifts, patent landscapes, and pipeline developments to navigate this complex environment effectively.

Key Takeaways

• The global fentanyl transdermal market is growing steadily but faces headwinds from regulations and market saturation.
• DURAGESIC-75's revenue trajectory is projected to decline marginally in the short term, with potential stabilization or growth through new formulations and emerging markets.
• Patent expiries and generic competition accelerate price erosion; product innovation remains critical.
• Regulatory trends favor abuse-deterrent formulations, influencing future development pipelines.
• Strategic diversification and compliance investments are essential for sustained profitability.

FAQs

Q1: How will patent expirations impact DURAGESIC-75 sales?
A: Patent expiries typically lead to increased generic competition, causing significant price erosion and revenue reduction unless the original manufacturer innovates or secures new patents for enhanced formulations.

Q2: What regulatory factors could influence the future market for DURAGESIC-75?
A: Stringent prescribing guidelines, abuse-deterrent drug mandates, and controlled substance regulations can limit prescriptions, while approval of new formulations may open new market segments.

Q3: Are there promising pipeline products related to DURAGESIC?
A: Yes. Ongoing R&D focuses on abuse-deterrent formulations, longer-acting patches, and alternative delivery systems potentially extending market viability.

Q4: Which regions present the most growth opportunities?
A: Emerging markets like China, India, and Brazil are expanding their pain management needs and regulatory frameworks are gradually liberalizing, offering growth potential.

Q5: How do market risks compare between DURAGESIC-75 and other high-dose opioid patches?
A: Both face similar risks from regulatory scrutiny, patent challenges, and litigation, but market share advantages of established brands like DURAGESIC provide some buffer against generic competition.

---

References

[1] MarketLine Reports, "Global Fentanyl Transdermal Patch Market," 2023.